Many studies showed that increasing DNA damage of cancer cell and inhibiting HR repair pathways are the major methods to improve the treatment efficiency of olaparib (Ola) in BRCA1 wild-type ovarian cancer 19-21. This evidence concerns the gene BRCA1 and ovarian carcinoma.